Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,943,751 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,943,751 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,942,323 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,942,323 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,966,320 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,966,320 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,976,036 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,976,036 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,958,949 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,958,949 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2024 Filed Mar 22, 2024 21:18 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherPerformance-Based Restricted Stock Units · Derivative | 1,130,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000068 · wk-form4_1711142280.xml · derivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,130,382 shares Expires 2027-05-26 F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · kind: This performance stock unit award that was granted on May 26, 2020 was cancelled and forfeited effective as of March 18, 2024. This was for good and valuable consideration, including continued employment with the Company. F2 · shares: This performance stock unit award that was granted on May 26, 2020 was cancelled and forfeited effective as of March 18, 2024. This was for good and valuable consideration, including continued employment with the Company. F3 · derivative.exercise_date: One-third of the granted performance-based restricted stock units vested and converted into shares of common stock based on the Issuer's achievement of the stock price milestone, as certified by the Issuer's compensation committee on January 2, 2021. Read SEC document |
| July 21, 2023 Filed Feb 14, 2024 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 36,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000032 · wk-form5_1707871552.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,086,009 F1 · shares: These shares were transferred from the Eltoukhy Investments, L.P. to The Eltoukhy Children's Trust A, The Eltoukhy Children's Trust B, and the remainder to the account of Helmy Eltoukhy. Read SEC document |
| July 21, 2023 Filed Feb 14, 2024 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 164,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000032 · wk-form5_1707871552.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Eltoukhy Children's Remainder Trust B Disclosed balance after: 164,716 F1 · shares: These shares were transferred from the Eltoukhy Investments, L.P. to The Eltoukhy Children's Trust A, The Eltoukhy Children's Trust B, and the remainder to the account of Helmy Eltoukhy. Read SEC document |
| July 21, 2023 Filed Feb 14, 2024 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 164,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000032 · wk-form5_1707871552.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Eltoukhy Children's Remainder Trust A Disclosed balance after: 164,288 F1 · shares: These shares were transferred from the Eltoukhy Investments, L.P. to The Eltoukhy Children's Trust A, The Eltoukhy Children's Trust B, and the remainder to the account of Helmy Eltoukhy. Read SEC document |
| July 21, 2023 Filed Feb 14, 2024 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 365,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000032 · wk-form5_1707871552.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 0 F1 · shares: These shares were transferred from the Eltoukhy Investments, L.P. to The Eltoukhy Children's Trust A, The Eltoukhy Children's Trust B, and the remainder to the account of Helmy Eltoukhy. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:24 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 8,600 | $26.15 | $224,927.84 |
DisclosureSEC source: 0001576280-23-000040 · wf-form4_167900188171006.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,049,238 F2 · price: Represents the weighted average price of shares purchased at prices that ranged from $26.13 to $26.27. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:24 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 84,452 | $26.33 | $2,223,908.30 |
DisclosureSEC source: 0001576280-23-000040 · wf-form4_167900188171006.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040,638 F1 · price: Represents the weighted average price of shares purchased at prices that ranged from $26.245 to $26.50. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 100 | $98.00 | $9,800.00 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956,186 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 14,900 | $96.83 | $1,442,774.45 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956,086 F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $96.50 to $97.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 5,000 | $95.50 | $477,500.00 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,941,186 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 5,000 | $94.00 | $470,000.00 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936,186 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 26,394 | $93.04 | $2,455,811.25 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,931,186 F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $92.88 to $93.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 3,106 | $92.23 | $286,481.29 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904,792 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.88 to $92.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 12,409 | $98.75 | $1,225,445.83 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,901,686 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $98.71 to $98.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:07 UTC | Guardant Health, Inc. GH · Entity 3238 | PurchaseCOMMON STOCK | 37,591 | $97.90 | $3,680,316.78 |
DisclosureSEC source: 0001576280-21-000109 · wf-form4_163771242610324.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,277 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $97.445 to $98.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 23:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 23,923 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001576280-21-000086 · wf-form4_162924134465478.xml · derivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,612 Underlying: COMMON STOCK · 23,923 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 23:02 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 23,923 | $4.18 | $99,998.14 |
DisclosureSEC source: 0001576280-21-000086 · wf-form4_162924134465478.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,851,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired by the Reporting Person through a cash exercise of a vested Stock Option Award. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 751 | $160.01 | $120,167.06 |
DisclosureSEC source: 0001576280-21-000045 · wf-form4_161947291051916.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827,763 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.00 to $160.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,388 | $160.12 | $1,182,993.16 |
DisclosureSEC source: 0001576280-21-000045 · wf-form4_161947291051916.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,828,514 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.00 to $160.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,373 | $153.26 | $210,419.12 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835,902 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.13 to $153.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 23,879 | $152.76 | $3,647,865.88 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,837,275 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.13 to $153.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 18,150 | $151.80 | $2,755,090.14 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,861,154 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.13 to $152.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,556 | $150.93 | $838,543.19 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,879,304 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,900 | $149.11 | $581,539.53 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,884,860 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.824 to $149.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,500 | $148.35 | $519,232.35 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,888,760 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.77 to $148.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,168 | $152.11 | $329,771.44 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892,260 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.885 to $152.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,677 | $151.30 | $1,161,550.83 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894,428 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.83 to $151.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,752 | $150.27 | $563,796.16 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,902,105 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.80 to $150.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 699 | $149.47 | $104,479.60 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,905,857 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.75 to $149.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,711 | $148.10 | $253,402.01 |
DisclosureSEC source: 0001576280-21-000044 · wf-form4_161913137014160.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,556 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.63 to $148.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 667 | $156.80 | $104,587.80 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 17 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,908,267 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.58 to $157.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,594 | $156.00 | $716,663.08 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 16 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,908,934 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.58 to $156.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,901 | $155.29 | $450,490.78 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,913,528 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.58 to $155.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,813 | $153.91 | $279,046.44 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916,429 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.50 to $154.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 22,280 | $153.03 | $3,409,561.87 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,918,242 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.50 to $153.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,555 | $152.01 | $1,300,467.79 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,940,522 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.50 to $152.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,122 | $151.17 | $1,530,096.18 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949,077 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.50 to $151.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 100 | $159.61 | $15,960.50 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,959,199 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.60 to $159.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 33,093 | $158.70 | $5,251,822.70 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,959,299 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.49 to $159.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,156 | $158.01 | $1,762,795.26 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,992,392 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.48 to $158.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,774 | $157.09 | $1,064,142.56 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,003,548 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.48 to $157.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,700 | $161.12 | $273,905.02 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010,322 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.975 to $161.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 27,191 | $160.31 | $4,358,899.48 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,012,022 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.95 to $160.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 64,664 | $159.08 | $10,286,626.26 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,039,213 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.945 to $159.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 43,845 | $158.38 | $6,944,157.95 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,103,877 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.945 to $158.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,465 | $157.12 | $2,115,560.21 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,147,722 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.94 to $157.925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:14 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,242 | $156.67 | $977,946.62 |
DisclosureSEC source: 0001576280-21-000043 · wf-form4_161887406296017.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,161,187 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.94 to $156.905, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 20,101 | $158.00 | $3,175,970.06 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 16 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167,429 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.00 to $158.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,047 | $157.28 | $951,087.88 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,187,530 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.94 to $157.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,591 | $156.39 | $1,656,320.14 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,193,577 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.92 to $156.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.